The role of glial cells in neuronal death has become a major research interest. Glial cell activation has been demonstrated to accompany cerebral ischemia. However, there is disagreement whether such gliosis is a cell death or a neuroprotective response. In the present study, we examined alterations in glial cell responses to the reported neuroprotective action of the free radical scavenger, melatonin, against cerebral ischemia. Adult male Wistar rats were given oral injections of either melatonin (26 mol/rat) or saline just prior to 1 h occlusion of the middle cerebral artery (MCA), then once daily for 11 or 19 consecutive days. At 11 and 19 days after reperfusion of the MCA, randomly selected animals were killed and their brains removed for immunohistochemical assays. Melatonin significantly enhanced survival of glial cells (as revealed by glial cell specific markers, glial fibrillary acidic protein and aquaporin-4 immunostaining) at both time periods postischemia, and the preservation of these glial cells in the ischemic penumbra corresponded with a markedly reduced area of infarction (detected by immunoglobulin G and hematoxylin-eosin staining), as well as increased neuronal survival. The ischemia-induced locomotor deficits were partially ameliorated in melatonin-treated animals. In vitro replications of ischemia by serum deprivation or by exposure to free radical-producing toxins (sodium nitroprusside and 3-nitropropionic acid) revealed that melatonin (10 g/ml or 100 M) treatment of pure astrocytic cultures significantly reduced astrocytic cell death. These results suggest a potential strategy directed at enhancing glial cell survival as an alternative protective approach against ischemic damage.-Borlongan, C. V., Yamamoto, M., Takei, N., Kumazaki, M., Ungsuparkorn, C., Hida, H., Sanberg, P. R., Nishino, H. Glial cell survival is enhanced during melatonininduced neuroprotection against cerebral ischemia. FASEB
Until recently, the role of glial cells in integrity and degeneration of the central nervous system has not been well elucidated, and accumulating evidence now suggests glial cells are critical to neuronal survival. In the developing central nervous system, astrocytes have been shown to guide correct migration and proliferation of neurons, whereas in the adult, astrocytes have been implicated in maintenance of neuronal homeostasis and synaptic plasticity (1, 2) . Astrocytes have been demonstrated in vitro to possess receptors (3, 4) as well as signaling molecules that can trigger neuronal messages that are key to cell survival (5) or death (6) . Examination of cell death has been primarily investigated using pure neuronal cell cultures; when in vivo studies are conducted, models of neurodegeneration have been evaluated mainly using neuronal death as sole index. Of note, mixed astrocyte-neuronal cultures that resemble the in vivo condition appear to promote better neuronal survival than pure neuronal cultures (7, 8) .
The identification of trophic factors, such as glial cell-line derived neurotrophic factor (GDNF) (9), has prompted investigations into possible therapeutic actions of glial cells. Glial cells are the main source of transforming growth factor ␤ (in which GDNF is a subfamily member) and astrocytes have been shown to release many growth factors under normal conditions or in response to brain injury (10, 11) . Accordingly, experimental treatment strategies for neurodegenerative disorders such as Parkinson's disease have exploited the support and trophic factor properties of glial cells (12) . For example, the maturation of neurite axons and astroglial fibers from embryonic grafts is characterized by donor glial cells remaining proximal to the grafted site (13, 14) , thus allowing axons of passage to reach host targets (15) . Transplantation of astrocytes transfected with the gene synthesizing and secreting GDNF or the dopamine precursor L-DOPA have been demonstrated to provide enhanced amelioration of parkinsonian symptoms (16) . Grafted embryonic dopaminergic neurons combined with infusion of astrocytic growth factor or GDNF have similar positive effects.
Additional properties of astrocytes include their ability to control water and to reduce glutamate toxicity (17, 18) . Astrocytes siphon excess extracellular water and potassium ions, then either redistribute them to their networks or excrete them into the blood vessels. They also transport glutamate into soma and, in the process, detoxicate glutamine by converting toxic OH Ϫ into less harmful H 2 O 2 . These findings suggest that glial cells can exert protective effects on neuronal survival by their trophic, siphoning, and detoxicating actions.
Cerebral ischemia has been associated with marked cell damage characterized by widespread activation of glial cells or reactive gliosis. There is disagreement as to whether such gliosis is a cell death or a neuroprotective response. In experimental models of ischemia, some studies have reported that astrocytes are more resistant than neurons (19, 20) , but other investigations provide equally compelling evidence of a higher vulnerability of astrocytes than neurons (21, 22) . Because of the presence of dense glial cell accumulations in the ischemic penumbra, their role in propagating or limiting the size of infarction is widely debated (11) . Notwithstanding, the highly glial cell-populated ischemic penumbra has been suggested to be a conducive target site for cellular treatment intervention (23, 24) . Transplantation of fetal (25, 26) or cultured neurons (27) near or within the ischemic penumbra has been found to induce behavioral recovery in ischemic animals. In the clinic, the ischemic penumbra is also targeted by anticoagulants or thrombolytics to dissolve blood clots (28) . Although drug therapy remains the treatment of choice for stroke patients, there has been no conclusive evidence of longlasting motor and cognitive improvement with any of the current drugs (28) . Thus, stroke remains one of the main causes of death in the world and finding ways to rescue the central nervous system after ischemia has been a major research endeavor.
Recent studies have implicated the abnormal accumulation of free radicals in neurodegenerative disorders. Free radical scavengers have been shown to protect against cell death (29, 30) . Melatonin is a highly potent free radical scavenger (31, 32) and its administration to rats has been found to be effective against neurotoxicity (33) (34) (35) . The present study explored the utility of melatonin in ameliorating the deficits associated with cerebral ischemia, which are in part mediated by aberrant free radicals and/or reactive nitrogen and reactive oxygen intermediates (e.g., production of nitric oxide, hydrogen peroxide, peroxynitrite). Recent reports have demonstrated protective effects of melatonin against experimental ischemic damage (29, 36 -39) and a deficiency in melatonin has been suggested in stroke patients (40) . To date, the proposed mechanism for the protective action of melatonin involves a direct free radical scavenging effect on neurons. Because of obvious alterations in glial cells after cerebral ischemia, we hypothesized that if melatonin elicited therapeutic effects against cerebral ischemia, then it could exert protective actions on glial cells, as well as the neurons. The present results offer support for the emerging view that glial cells are equally active participants as neurons in the maintenance of a functional central nervous system.
MATERIALS AND METHODS

Animals
Adult male Wistar rats weighing 250 -300 g were used in these experiments. Animals were kept under a 12-12 h light/dark cycle and allowed free access to food and water. Animal care was in accordance with NIH guidelines for use of animals in research. Animals were randomly assigned to melatonin or saline treatment condition (nϭ11 per group). An additional group of animals (nϭ8) served as controls and underwent a sham surgery (similar to the ischemia procedure described below, except that the embolus was not inserted); four animals were treated with melatonin, whereas the other four received saline treatment following the same drug regimen used for the ischemic animals (see below).
Ischemia
Ischemia surgery has been reported elsewhere (25) (26) (27) . Briefly, rats were anesthetized by halothane and an embolus (a 4 -0 Ethicon nylon filament, with tip diameter tapered to the size of a 26G needle) was inserted from the external carotid, via the common carotid, to the base of the right middle cerebral artery (MCA) to stop the blood flow to the MCA. During the ischemia, anesthesia was cut off and animals were allowed to recover for 1 h; behavioral tests (see below) were performed to confirm successful unilateral ischemia. After 1 h of ischemia, the animals were reanesthetized with halothane; the embolus was withdrawn, the blood reperfusion was established, and the skin was sutured. The body temperature of animals was maintained at 37°C throughout the surgery until they recovered from anesthesia.
Drugs
Melatonin (Sigma, St. Louis, Mo.) was dissolved in saline (using a vortex) and administered orally (26 mol/rat) just prior to 1 h MCA ischemia, then once daily for 11 or 19 consecutive days. Saline was administered similarly to the other treatment group. Each animal received an intragastric application (using an 18 gauge gavage) of 1 ml of the solution.
Behavioral tests
For behavioral examination, the forelimb akinesia (also called postural tail-hang test) and spontaneous rotational tests were evaluated during MCA occlusion (i.e., during 1 h embolism) and again at 11 and 19 days after ischemiareperfusion injury. Detailed description and specific criteria for each test to determine successful ischemia have been reported elsewhere (27) . Briefly, the forelimb akinesia test involved holding the animal by the tail and noting the positions of the forelimbs. Animals with MCA occlusion demonstrate a characteristic posture with the left forelimb clipped to their chest muscles while the right forelimb is stretched out. For the spontaneous rotational test, the animal was placed in a box made of transparent Plexiglas (40ϫ40ϫ35.5 cm) and the direction of the animal's rotation was noted over a five-minute session. Two full turns (tight ipsiversive rotations toward the side of the ischemia) per minute indicated complete MCA occlusion.
Immunohistochemistry
Detailed description of immunohistochemistry was reported elsewhere (41, 42) . Briefly, animals under deep anesthesia were perfusion-fixed transcardially with 4% paraformaldehyde at 11 or 19 days after ischemia. Brains were removed and cryosections (50 M) were processed for immunohistochemistry by a standard ABC method using anti-GFAP antibody (Dakopotts, Roskilde, Denmark), anti-MAP2 antibody (Chemicon, Temecula, Calif.), biotinylated rabbit anti-rat immunoglobulin G (IgG; Vector Lab, Burlingame, Calif.), and anti-aquaporin-4 antibody. Alternate sections were processed for hematoxylin-eosin (H&E) staining. The extent of infarction was assessed by measuring the maximum infarcted area (IgG extravasation) in each animal using an NIH imaging system.
Astrocyte culture
The method for culturing primary astrocytes is described elsewhere (43) . Briefly, the cortical tissue from neonatal rats was dissected and meninges were removed. The tissue was mechanically dissociated and trypsinized at 37°C for 20 min. Trypsin action was stopped by soybean trypsin inhibitor with DNase. The pellet was suspended in complete medium (DMEMϩ10% FBS), plated on sterile culture flask, and kept in an incubator with 5% CO (2) at 37°C. After confluence, the culture flask was shaken to eliminate cells other than astrocytes, then the cells were dissociated and seeded in 24-well culture plates in complete medium. After confluence, the medium was changed to DMEM/F12 without serum. Sodium nitroprusside (SNP; a direct nitric oxide donor; 100 M or 1 mM) or 3-ntiropropionic acid (3-NP; a succinate dehydrogenase inhibitor and peroxynitrite donor; 1.7 mM) with or without melatonin (10 g/ml) were loaded to indicated wells.
MTT and neutral red assays
To investigate the protective effects of melatonin on astrocytes against the cytotoxicity of 3-NP or cell death after serum deprivation, pure astrocytes were cultured on 96-well dish at a density of 10,000/well (DMEM/F12ϩ10% FBS). Treatment with 3-NP (6 mM) or serum deprivation with or without melatonin (100 M) was initiated at 3 days after plating. 3-(4,5-Dimethyl thiazoly) 2,5-diphenyl-tetrazolium bromide (MTT) assay, which reflects the activity of succinate dehydrogenase (Cell Counting Kit-8, Dojindo, Japan), was carried out 10 days after serum deprivation. Neutral red assay, instead of MTT, was performed at 3 days after 3-NP treatment because 3-NP interferes with the MTT assay by also inhibiting succinate dehydrogenase activity (44, 45) . MTT assays were conducted in two independent experiments (nϭ8 samples); neutral red assays involved three independent experiments (nϭ12 samples).
Statistical analyses
Analyses of variance were used to reveal statistical significance between the two treatment groups over the two test periods. Since we found no significant differences in the behaviors or histological disturbances in animals within group at both time periods, we combined data from both time periods within group for subsequent analyses. Scheffe's t tests were used to compare the two groups in the final analyses of the in vivo data, as well as for analyzing the in vitro data. Differences were considered significant at P Ͻ 0.05. Values are expressed as mean Ϯ standard error (se).
RESULTS
Behavioral and histological examinations of the control animals that were introduced to the sham surgery revealed no observable abnormalities. Treatment with melatonin or saline in these sham animals did not produce any detectable behavioral abnormality or histological disturbances. Thus, subsequent analyses focused on the two groups of animals that underwent ischemia. Any alterations in behavior or brain histology in these animals could be conclusively established as ischemia-induced abnormalities, whereas the absence or reduction thereof in animals receiving melatonin could be interpreted as protective effects of the drug.
Melatonin markedly reduced infarctions
Histological analyses using H&E and IgG immunostaining of brains revealed that ischemic animals treated with melatonin showed significantly smaller infarcted areas than those of vehicle-treated ischemic animals ( Figs. 1 and 2 ). This significant reduction of infarction by melatonin was consistently noted at both days 11 and 19 after ischemia/reperfusion injury. Both cortical and striatal infarcted areas were significantly reduced in melatonin-treated animals, with the cortex displaying more sensitivity to melatonin protection than the striatum. Using NIH imaging, we measured the maximum infarcted area in serial sections of the forebrain of each animal. Melatonin-treated animals exhibited 5.5 Ϯ 4.5 mm 2 (mean Ϯ se) and 7.2 Ϯ 4.0 mm 2 whereas saline-treated ischemic animals displayed 14.5 Ϯ 2.0 mm 2 and 10.6 Ϯ 3.0 mm 2 cortical and striatal infarcted areas, respectively. Thus, melatonin decreased by ϳ60% and 30% the area of cortical and striatal infarction (Fig. 1E) .
Melatonin partially blocked glial cell loss and gliosis produced by ischemia
Histological disturbances in glial cells and neurons were monitored using glial fibrillary acidic protein (GFAP) and microtubule associated protein-2 (MAP2) immunostaining. Melatonin-treated animals showed less glial cell loss, as well as gliosis (Fig. 2D, E) compared to vehicle-treated animals ( Fig. 2A, B) . Although both groups of animals displayed surviving MAP2-positive pyramidal neurons in the cortex (Fig.  2C, F ) , glial cell support to these neurons was detected in melatonin-treated animals, but not in vehicle-treated animals. The reduction in glial cell loss and gliosis in melatonin-treated animals were noted at 11 and 19 days postischemia/reperfusion injury.
Figure 2. Glial cell death and gliosis in ischemic brain. A-C)
Saline-treated ischemic animal; D-F ) melatonin-treated ischemic animal. GFAP immunostaining (A, B, D, E); MAP2 immunostaining (C, F ). In saline-treated ischemic animals, GFAP-positive astroglias were not detected in the ischemic core (lateral striatum and dorsolateral cortex) and gliosis was prominent in medial striatum and cortical penumbra (A). Glial loss and gliosis were markedly reduced in melatonintreated animals (D). B, E) Higher magnifications of the lateral cortices of panels A and D, respectively. C, F) (Adjacent sections of panels B and E, respectively) MAP2 immunostaining demonstrating survival of pyramidal neurons in the cortex of saline-treated and melatonin-treated ischemic animals, respectively. Scale bars: 1 mm in panels A, B and 100 m in panels B, C, E, F. A, B) . Using an NIH imaging system, the area of the IgG extravasation was quantified in the largest damaged area (frontal section) of each animal. Histograms show mean values of area of IgG extravasation in cortex (dotted) and striatum (solid) in saline-treated and melatonin-treated ischemic animals. The extent of the IgG extravasation in the cortex was significantly smaller in melatonin-treated animals (E). These results were noted at 11 and 19 days after ischemia-reperfusion injury. Bars represent mean values Ϯ se from combined experiments at 11 and 19 days after ischemia (nϭ11 per group). Asterisk indicates statistical significance at P Ͻ 0.05. Scale bar, 1 mm in panel A.
Interactions between glial cells and neurons in the ischemic brain
Three typical regions could be discerned after ischemia-reperfusion injury in both striatum and cortex, which reflected glial cell-neuron interactions (Fig.  3) . These areas included the ischemic core, where there was no detectable survival of neurons and glial cells (Fig. 3A, B, far lateral) , the ischemic penumbra, which was highly populated by glial cells (Fig. 3B, left  end) , and the zone between the ischemic core and penumbra comprised of surviving neurons devoid of glial cells (Fig. 3C-E) . For example, surviving pyramidal neurons were noted next to the ischemic penumbra where there was a near absence of astroglial support as revealed by no detectable GFAPpositive astroglial cells (Fig. 3D) . Immediately adjacent to this pure neuronal zone were areas of complete cell/tissue loss (infarction). Interspaced between the pure neuronal zone and the area of gliosis was a region containing surviving neurons that were individually enveloped by glial cells exemplifying glial cell support to neuronal survival (Fig.  3E, F ) . Thus, the absence of glial cells in ischemic regions corresponded to areas near the ischemic core, whereas their presence coincided with the ischemic penumbra and areas near intact tissues. These distinct ischemic areas were noted at 11 and 19 days postischemia/reperfusion injury.
Regional distribution of glial cells in response to ischemia
Because the cortex was primarily affected by melatonin, we further investigated the distribution of glial cells in the remodeling of this region after ischemia/ reperfusion injury. In saline-treated ischemic animals, migrating glial cells were detected at the edge of the lateral ventricular zone of both hemispheres as revealed by immunostaining with GFAP (a marker for astroglial cells) and aquaporin-4 (a marker for water channel protein of astroglial cells) (Fig. 4A, B) . Regional analyses of the cortex revealed that astroglial cells were almost undetectable and only neurons remained close to the ischemic core (Fig. 4Aa) . At the edge of cortical ischemic penumbra, astroglial cells exhibited dense immunoreactivity (gliosis) characterized by several processes with multiple branches/arbors and dark nuclei (Fig. 4Ab) . Similar astroglial cells were noted near the edge of the ventricular zone of the ischemic side, but their soma were stout and processes were not as elaborate as those residing near the edge of the ischemic penumbra (Fig. 4Ac) . Astroglial cells were also detected on the contralateral cortex corresponding to ischemic penumbra (Fig. 4Ae ) and ventricular zone (Fig. 4Af ) , but with less elaborate processes and lightly stained nuclei. Normal resident glial cells were detected in the contralateral intact cortex corresponding to ischemic core (Fig. 4Ad) . Aquaporin-4 immunoreactivity resembled the GFAP pattern. Near total absence of aquaporin-4 immunoreactivity, with only few lightly stained neuronal somas, was seen close to the ischemic core (Fig. 4Bg) , whereas in the corresponding contralateral intact side, normal aquaporin-4 immu- noreactivity was detected (Fig. 4Bj) . At the edge of the ischemic penumbra, as well as in the contralateral corresponding region, a strong aquaporin-4 immunoreactivty was detected (Fig. 4Bh, k) . A denser aquaporin-4 immunoreactivity with condensed glial soma was noted near the edge of the ventricular zone of both hemispheres (Fig. 4i) . The gradient of GFAP and aquaporin-4 immunoreactivity delineated distinct regions where viable glial cells remained after the ischemia/reperfusion injury. Specifically, the ventricular zone (gliogenesis site) and the edge of the ischemic penumbra were heavily populated by glial cells. These observations were consistent for both days 11 and 19 after ischemia.
In vitro replication of melatonin protection against ischemia
Ischemia/reperfusion damage entails nitric oxide or peroxynitrite production, as well as interruption in cerebral blood flow, and these cellular mechanisms were mimicked in vitro by treatments of SNP or 3-NP and by serum deprivation, respectively. Pure astrocytic cell cultures treated with melatonin (10 g/ml) were protected against cell death induced by SNP, 3-NP, or serum deprivation (Fig. 5) . Treatment with SNP (1 mM or 100 M) resulted in marked astrocytic cell death at 36 h or 72 h, but cotreatment with melatonin almost completely blocked the toxicity of SNP at both time periods. Treatment with 3-NP (1.7 mM) also induced astrocytic cell death at 96 h, but cotreatment with melatonin (10 g/ml) markedly reduced the 3-NP toxicity. Melatonin also substituted for serum, as revealed by survival of astrocytes after 10 days of serum deprivation. MTT and neutral red assays further demonstrated that melatonin (100 M) had protective effects against 3-NP (6 mM) toxicity) (Fig. 6A) and cell death after serum deprivation (Fig. 6B) . These protective effects of melatonin on pure astrocyte cell cultures parallel the in vivo observations that melatonin preserved the survival of glial cells after ischemic injury.
Partial maintenance of normal motor functions by melatonin
All animals used in the present study were impaired in their motor functions when examined during the 1 h occlusion of the right MCA. The demonstration of asymmetrical behaviors during the occlusion period in both melatonin-and saline-treated ischemic animals is indicative of successful ischemic stroke (46) , and such functional deficits are stable for at least 6 months (27) . When evaluated at 11 and 19 days postischemia/reperfusion injury, the majority of melatonin-treated ischemic animals displayed near normal motor functions compared with salinetreated ischemic animals. In the forelimb akinesia test, only 4 of 11 melatonin-treated animals exhibited impairment compared to 8 of the saline-treated ischemic animals. In the rotational test, only 1 of 11 Pyramidal neurons were located close to the ischemic core survive without the support of astroglia (a). Reactive gliosis with strong GFAP immunoreaction was detected in the ischemic penumbra (b). Moderate to strong gliogenesis was noted in the dorsolateral edge of the lateral ventricle, and glial cells in this area exhibited round/stout soma and short processes (c, f ). Astrocytes located in the intact cortex corresponding to the ischemic penumbra showed a relatively high GFAP immunoreaction (e). Typical skinny stellate-shaped astrocytes were seen in the intact cortex corresponding to the ischemic core (d). No aquaporin-4 positive astrocytes were detected near the penumbra of ischemia (g). Compared to a typical aquaporin-4 immunoreaction pattern (strong immunoreaction around blood vessels, but weak reaction around neuropils) in contralateral intact cortex (j), the immunoreaction of aquaporin-4 in ischemic penumbra was strong around blood vessels, as well as in soma and neuropils (h). Strong aquaporin-4 immunoreaction on astrocytic soma with short processes in dorsal edge of the lateral ventricles (i, l). In the intact cortex corresponding to the ischemic penumbra, moderate aquaporin-4 immunoreaction was detected not only around the blood vessels, but also in neuropils (k). Scale bars, 1 mm in panel A, 50 m in panel l. melatonin-treated ischemic animals displayed behavioral abnormality compared to 6 of 11 saline-treated ischemic animals. Thus, both behavioral tests revealed that melatonin treatment ameliorated ischemia-induced behavioral deficits.
DISCUSSION
The present study demonstrated that glial cells were protected by melatonin against cerebral ischemia.
Glial cell loss and gliosis were markedly reduced in animals treated with melatonin, whereas severe glial cell loss in the ischemic core and prominent gliosis in the ischemic penumbra were noted in the salinetreated ischemic animals. Although the present study parallels recent reports of melatonin-induced neuroprotection, it offers a novel cellular mechanism underlying the beneficial effects of melatonin against degeneration of the central nervous system. At least in the present animal model of ischemia, we showed that glial cells appeared more sensitive than neurons to degenerative and neuroprotective processes. One can speculate whether affording protection to glial cells is one pathway that melatonin could exert its overall protective effects, which may work in concert with other mechanisms including the reported direct action of melatonin on neurons against ischemia-induced cell death (47, 48) .
Three major findings were noted in the present study that implicated the critical role of glial cells in neurodegeneration after ischemic stroke and in neuroprotection rendered by melatonin. First, the disappearance of GFAP-positive glial cells, but with survival of neurons, within a few days after the ischemia/reperfusion injury indicates that glial cells were more vulnerable than neurons. One may argue that ischemia only induced some structural changes in astroglial cells that resulted in decreased antigenicity of GFAP protein, which would suggest that glial cell death did not precede neuronal death. However, the aquaporin-4 immunostaining (also a specific marker of astrocytes in the brain), conducted at the same time as that of GFAP, exhibited the same pattern as GFAP immunoreactivity, suggesting that glial cell loss or gliosis occurred prior to neuronal death.
The second observation is that there were differential alterations in glial cells in ischemic brain . Protective effect of melatonin on astrocytic cell death measured by neutral red and MTT assays. A) Melatonin (ML, 100 M) has protective effects against 3-NP toxicity (6 mM) (PϽ0.05 for 3-NP vs. 3-NPϩML). Neutral red assays (nϭ12 from three independent experiments) were carried out 3 days after 3-NP treatment. B) Cell death after serum deprivation (serum free, SF) was significantly reduced by melatonin (ML, 100 m) (PϽ0.001 for SF vs. SFϩML 100 m). MTT assays (nϭ8 from duplicate independent experiments) were performed at 10 days after serum deprivation. Asterisks indicate statistical significance: * ϭ P Ͻ 0.05, ** ϭ P Ͻ 0.001.
areas. The cortical infarction was reduced more significantly than that in the striatum after melatonin treatment. The presence of higher number of glial cells in the ischemic cortex than that of the ischemic striatum in animals that were treated with melatonin might have amplified the cortical protection. Experimental evidence points to regional differences in density and viability of astrocytes. For example, the ratio of glial cells to neurons is about one to one in the rat striatum (49) , but glial cells outnumber the neurons in the cortex of rat (50) or human (51) , especially in the aging brain (52) . Because homotypic glial cells were shown to provide better dendritic growth (53) , the higher number of cortical astrocytes than striatal astrocytes may account for better protection of the cortex than the striatum from ischemia. The presence of functional glial cells in specific areas of the brain in response to brain injury may explain also the observed differential protection. In the adult brain, stem cells remain in the subventricular zone of the forebrain and the dentate gyrus. From the former, it has been reported that the proliferating cells mainly develop into astrocytes, which then migrate into other brain areas (54) . It is possible that an ischemic insult could activate an enhanced gliogenesis and migration. In the ischemic striatum, reactive astrocytes have been detected in the medial aspect as early as 4 days after postischemia/reperfusion injury, but it required an extra 3 days for them to reach the lateral aspect (55) . This delay in the migration of astrocytes to the lateral striatum might have adversely contributed to fully protecting the striatum. Alternatively, cortical cells may be more sensitive than striatal cells to the presence of glial cells as revealed by better survival of fetal cortical cells than fetal striatal cells when cultured in astroglial enhanced medium (56) . Taken together, these data may explain the preferential protection of the cortex over the striatum.
The third major point of the present study is that the protection of glial cells afforded by melatonin is supported by behavioral and in vitro data. The reductions in glial cell loss and gliosis in melatonin-treated ischemic animals were paralleled by the observations of near normal motor functions in these animals. The ischemia-induced behavioral deficits seem to be mediated largely by a functional cortex because melatonin-treated ischemic animals had minimal cortical infarction compared to saline-treated ischemic animals. Even though these animals also displayed a reduction in total striatal infarction, the lateral aspect of the striatum was still clearly damaged, suggesting that protection of the cortex may be sufficient for normalization of motor behaviors. The absence of behavioral protection by melatonin during the 1 h occlusion indicates that the drug (administered once before the arterial occlusion) did not block the functional deficits associated with the acute ischemic insult caused by interruption of cerebral blood flow. It appears that melatonin was protective against secondary cell death processes.
The positive in vivo effects of melatonin were replicated in vitro as revealed by continued survival of melatonin-treated astrocytes after serum deprivation or exposure to toxins (3-NP and SNP), which paralleled some in vivo cellular events observed in response to ischemia/reperfusion injury. Recent reports have demonstrated the efficacy of melatonin against ischemic damage (29, 36, 37) . Melatonin is an effective free radical scavenger and indirect antioxidant (29, 30, 33-37, 57, 58) . Hydroxyl radicals (generated by hydrogen peroxide via the Fenton reaction) and peroxynitrite anions are scavenged by melatonin (31, 57) . In addition, it blocks singlet oxygen-induced toxicity (59) . Lipid peroxidation in the brain produced by intoxication of free radical generating agents is also reduced by melatonin (35, 60) . These studies demonstrate that melatonin directly protects neural tissue from free radical toxicity. To date, however, these studies have not examined alterations in glial cells after melatonin treatment. The possibility exists that enhanced survival of glial cells after melatonin treatment may confer protection to the injured neurons. The enveloping action of glial cells on neurons might aid in the homeostasis of the neuronal cell membrane by siphoning excess potassium or by enhancing water handling capacity (Fig. 7) . In addition, glial cells may serve as cystine/glutamate antiporter system that can prevent glutamate toxicity (3, 4, 61) . Finally, glial cells can secrete trophic factors, including GDNF, which has recently been shown to protect against experimental cerebral ischemia (62). Thus, the combined buffering action, anti-glutamate toxicity transporter mechanism, and trophic factor-secreting potential of glial cells make them efficacious neuroprotective agents, and they could be recruited by melatonin to combat ischemia/reperfusion injury.
Are glial cells beneficial or detrimental to brain injury? There is experimental evidence on both sides making conclusions difficult on the role of glial cells in the central nervous system. For example, it has been argued that after a brain insult, repair of the injury site may be limited due to the nonpermissive condition elicited by reactive gliosis (63) . In response to injury, astrocytes or microglia secrete substances, such as basic fibroblast growth factor, transforming growth factor ␤ or interleukins, which have been demonstrated to exacerbate the degeneration of the injured site (64) . On the other hand, the same reactive gliosis has been shown to promote reparative effects in the injured brain. In response to excitotoxic lesions (65) or intraparenchymal infusion of basic fibroblast growth factor (66), reactive astrocytes are involved in removing degenerating axon terminals, but not axons of passage, from the neuropil. We have shown also that ongoing glial response may underlie the long-term functional recovery in transplanted parkinsonian rats (67) . The present results suggest that glial cells may participate in neuroprotection. However, we do not exclude the equally beneficial effects of exploiting protective or reparative strategies designed at directly manipulating neuronal survival. Rather, we suggest that a complete glial cell-neuron interaction model should be considered when studying the central nervous system during states of homeostasis and vulnerability.
From the basic research standpoint, the present results support the notion that glial cells are closely involved in brain injury. We now propose a dynamic interaction between glial cells and neurons during ischemia/reperfusion cell damage (Fig. 8) . The first stage consists of initial activation of glial cells and occurs within a few days after the ischemia/reperfusion process. The second stage, about 1 wk later, is characterized by intense glial cell loss that corresponds to the formation of the ischemic core. Surviving neurons enveloped by the remaining glial cells, both with pruned processes, can still be detected within the ischemic core. After total disappearance of glial cell support, the third stage ensues with the onset of infarction. It is critical therefore that treatment modalities, such as the present melatonin application, should be initiated during the period when glial cells are still present. Perhaps the limited efficacy of drug therapy may be due to the short period of time that glial cells can be rescued from cell death. Because injured but viable glial cells are found along the ischemic penumbra, immediate rescue of this region may promote better protection. Our better understanding of glial cells, including their narrow window of reversible injury and their location or migration pattern in the ischemic penumbra, can greatly optimize the treatment for stroke.
In summary, we demonstrate alterations in glial cells during a period of neuronal vulnerability to undergo cell death after cerebral ischemia. Melatonin treatment exerted neuroprotection against ischemia/reperfusion injury by maintaining survival of both glial cells and neurons. The present study highlights the potential to protect the central nervous system from stroke by rescuing glial cells in addition to neurons. However, glial cells appeared more vulnerable than neurons after ischemia/reper- Speculative interaction between astrocytes and neurons during ischemia: aquaporin-4 immunoreaction in astrocytes. In intact brain, strong aquaporin-4 immunoreaction is exhibited on astrocytic end-feet covering blood vessels, but weak immunoreactions are detected on soma and processes in neuropil (A). In the developing brain as well as in response to brain insult such as ischemia/reperfusion injury, aquaporin-4 immunoreaction is strongly expressed on soma of astrocytes that are located in the dorsolateral edge of the ventricle. Note the short processes of astrocytes during gliogenesis (B). In reactive astrocytes found in ischemic penumbra, strong aquaporin-4 immunoreactions are detected on end-feet, soma and processes in neuropil (C). N, neuron; A, astrocytes; V1 and V2, blood vessels. fusion injury and also more sensitive to neuroprotective treatment. Therapeutic agents directed at glial cell protection may provide clinical applications for treatment of stroke and neurodegenerative disorders. Partial protection against cerebral ischemia was established by melatonin and perhaps enhanced recovery can be achieved by a combination of therapies designed at maximizing glial cell-neuron interaction.
